| Recruitment status | Main results already published |
| Unique ID issued by UMIN | UMIN000004121 |
| Receipt No. | R000004320 |
| Official scientific title of the study | Reseach into the effects of sitagliptin on blood sugar control in patients with type2 diabetes |
| Date of disclosure of the study information | 2010/09/01 |
| Last modified on | 2017/03/03 (Ver. 20) |
| Basic information | ||
| Official scientific title of the study | Reseach into the effects of sitagliptin on blood sugar control in patients with type2 diabetes | |
| Title of the study (Brief title) | SPIRITS-J:Sitagliptin Registration Type2 Diabetes-Juntendo Collaborating Project | |
| Region |
|
|
| Condition | ||||
| Condition | Type2 Diabetes | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Others | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | Reseach into the effects of sitagliptin on blood sugar control in patients with type 2 diabetes in Japanese |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The change of HbA1c levels after prescribing sitagliptin |
| Key secondary outcomes | the incidence of cardio-, cerebro-vascular events or diabetes-related complications |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients with new onset or poorly controlled type 2 diabetes who are newly or additionally prescribed sitagliptin | |||
| Key exclusion criteria | 1.Patients sufferd from severe ketosis, diabetic coma or semi-coma within 6-month before participating the study
2.Patients sufferd from severe infection or trauma, and perioperative 3.Possible or definitive pregnant women or nursing mother 4.Serum creatine levels are 1.5mg/dL or more 5.Patients with history of hypersensitivity to any ingredients of sitagliptin tablets 6.Other patients deemed not appropliate for participating to the study by investigators |
|||
| Target sample size | 3000 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroyuki Daida |
| Organization | Juntendo University School of Medicine |
| Division name | Department of Cardiovascular Medicine |
| Address | 2-1-1 Hongo Bunkyo-ku Tokyo, Japan |
| TEL | 03-3813-3111 |
| daida@juntendo.ac.jp | |
| Public contact | |
| Name of contact person | Hirotoshi Ohmura |
| Organization | Juntendo University School of Medicine |
| Division name | Clinical Research Support Center |
| Address | 3-1-1 Hongo Bunkyo-ku, Tokyo |
| TEL | 03-3813-3111 |
| Homepage URL | http://www.juntendo.ac.jp/jcrc/index.html |
| juntencrc@juntendo.ac.jp | |
| Sponsor | |
| Institute | Juntendo University School of Medicine, Clinical Research Support Center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Waksman Foundation |
| Organization | |
| Division | |
| Category of Funding Organization | Non profit foundation |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 順天堂大学医学部臨床研究支援センター |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Main results already published | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | |
| Other related information | 1.The efficacy of sitagliptin monotherapy
2.The efficacy of sitagliptin classificating by combination therapy 3.The incidence rate of adverse event by sitagliptin |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000004320 |